Phoenix AZ – February 25, 2026 | By STAFF HERE PHOENIX WRITER
WHAT’S HAPPENING
What is Novo Nordisk changing regarding Ozempic, Wegovy, and Rybelsus prices in the U.S.?
Novo Nordisk will reduce the monthly list price for Ozempic, Wegovy, and Rybelsus to $675, effective January 1, 2027, in the United States.
When will these significant price reductions take effect in Arizona and the U.S.?
The new, lower list prices for these medications will become effective on January 1, 2027, across the U.S.
Why is Novo Nordisk reducing its drug prices for Phoenix area patients?
The company stated the price adjustments aim to enhance patient affordability and address access barriers, particularly for those with high-deductible health plans.
Are self-pay prices for Ozempic, Wegovy, and Rybelsus also decreasing?
No, these list price changes do not affect direct-to-patient, self-pay prices, which have already seen reductions through other channels.
Novo Nordisk is set to significantly lower the U.S. list prices of its popular GLP-1 medications Ozempic, Wegovy, and Rybelsus by up to 50%, starting January 1, 2027. These price cuts aim to improve affordability for patients in Arizona and nationwide, especially those with high-deductible plans. The move comes as the GLP-1 market becomes more competitive.
Novo Nordisk Announces Significant U.S. Price Cuts for Ozempic, Wegovy, and Rybelsus
Novo Nordisk plans to significantly reduce the list prices of its popular GLP-1 diabetes and weight-loss medications, Ozempic and Wegovy, by as much as 50% in the United States, effective January 1, 2027. The drugmaker will lower the monthly list price for various doses of Ozempic, Wegovy, and Rybelsus to $675, representing a 50% reduction for Wegovy and a 35% reduction for Ozempic from their current levels. This decision also applies to Rybelsus, an oral formulation for type 2 diabetes, with its price also decreasing to $675 per month, a reduction of approximately one-third.
Reasons for the Price Reductions
The company stated these price adjustments are intended to enhance affordability and address access barriers for patients, especially those with high-deductible health plans or co-insurance where out-of-pocket costs are directly tied to the list price. This move aligns with ongoing calls from private and public payers, as well as patients, for lower list prices. The effective date for these reductions, January 1, 2027, coincides with the implementation of new, lower prices for Ozempic and Wegovy under Medicare plans.
Increasing Competition in the GLP-1 Market
The decision by Novo Nordisk comes amidst an increasingly competitive landscape in the GLP-1 agonist therapy market. The company is actively competing with other pharmaceutical firms, notably Eli Lilly, which offers rival medications such as Mounjaro and Zepbound. These price reductions represent a strategic effort by Novo Nordisk to maintain its position and improve accessibility for its semaglutide-based treatments for obesity and type 2 diabetes.
Impact on Different Semaglutide Offerings
The new $675 monthly list price will apply across the full suite of Novo Nordisk’s semaglutide products available in the U.S., including both injectable and oral formulations of Wegovy for obesity, injectable Ozempic for type 2 diabetes, and its oral counterpart, Rybelsus. It is important to note that these list price changes do not impact direct-to-patient, self-pay prices, as those have already seen reductions through various channels.
Summary of Novo Nordisk Price Adjustments
| Drug | Indication(s) | Previous List Price (Monthly Est.) | New List Price (Monthly) | Reduction Percentage | Effective Date |
|---|---|---|---|---|---|
| Wegovy (injectable & oral) | Weight-loss/Obesity | Over $1,000 | $675 | Up to 50% | January 1, 2027 |
| Ozempic (injectable) | Type 2 Diabetes | Over $1,000 | $675 | 35% | January 1, 2027 |
| Rybelsus (oral) | Type 2 Diabetes | Varies | $675 | Approximately one-third | January 1, 2027 |
| Affected Market | U.S. Wholesale Acquisition Cost (List Price) | N/A | N/A | N/A | N/A |
| Unaffected Prices | Direct-to-patient, self-pay prices | N/A | N/A | N/A | N/A |
| Primary Beneficiaries | Patients with high-deductible health plans or co-insurance | N/A | N/A | N/A | N/A |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE PHOENIX WRITER
The PHOENIX STAFF WRITER represents the experienced team at HEREPhoenix.com, your go-to source for actionable local news and information in Phoenix, Maricopa County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Waste Management Phoenix Open, Cactus League Spring Training, and Arizona State Fair. Our coverage extends to key organizations like the Greater Phoenix Chamber of Commerce and Visit Phoenix, plus leading businesses in technology and healthcare that power the local economy such as Intel and Banner Health. As part of the broader HERE network, including HERETucson.com, we provide comprehensive, credible insights into Arizona's dynamic landscape.
